Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.76 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204416 | 0.87 | ADRB1 (0.78) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| Bisoprolol SCHEMBL6510329 | 0.87 | ADRB1 (1.00) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL233810 | 0.87 | ADRB1 (1.00) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL20961 | 0.87 | ADRB1 (1.00) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL20960 | 0.87 | ADRB1 (1.00) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| SCHEMBL11667770 | 0.87 | ADRB2 (0.88) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL16821829 | 0.86 | ADRB1 (0.98) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL3137111 | 0.86 | ADRB2 (0.98) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| Bisoprolol SCHEMBL4269272 | 0.86 | ADRB1 (0.98) | ADRB2ADRB1ADRB3PTGS1SLC6A2 | |
| SCHEMBL2594781 | 0.86 | ADRB2 (0.65) | ADRB2ADRB1ADRB3PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245112-A1 | NEUREGULIN-1/ANTI-HER3 ANTIBODY FUSION PROTEIN FOR USE IN THE TREATMENT OF HEART FAILURE | SALUBRIS BIOTHERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4630821-A2 | BIOMARKER-BASED SYSTEMS AND METHODS OF DRUG IMPACT ASSESSMENT FOR USE IN PERSONALISED HEALTHCARE | Randox Laboratories Ltd (GB) | 2025-10-15 | — | — | EP | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250228917-A1 | METHODS OF TREATING FIBROSIS AND ARRHYTHMIA WITH A NEUREGULIN-1 FUSION PROTEIN | SALUBRIS BIOTHERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250189526-A1 | SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | MEMED DIAGNOSTICS LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-12268718-B2 | Control of cellular redox levels | LABYRINTH HOLDINGS LLC | 2025-04-08 | — | — | US | disclosed |
| EP-4493580-A1 | METHODS OF TREATING FIBROSIS AND ARRHYTHMIA WITH A NEUREGULIN-1 FUSION PROTEIN | Salubris Biotherapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12188934-B2 | Signatures and determinants for diagnosing infections and methods of use thereof | MEMED DIAGNOSTICS LTD. (IL) | 2025-01-07 | — | — | US | disclosed |
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12048676-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220242815-A1 | COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | Instituto Carlos Slim de la Salud, A.C. (MX) | 2022-08-04 | — | — | US | disclosed |
| WO-2022136254-A1 | PHARMACEUTICAL PROFILER ARRAY FOR USE IN PERSONALISED HEALTHCARE | RANDOX LABORATORIES LTD (GB) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140677-A1 | COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140654-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220127576-A1 | COMPOSITIONS AND METHODS FOR STEM CELL THERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-04-28 | — | — | US | disclosed |
| EP-3986412-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | The Broad Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11246879-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulai Therapeutics, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220042994-A1 | SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | MEMED DIAGNOSTICS LTD. (IL) | 2022-02-10 | — | — | US | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048676-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | ADRB2 4151/4885ADRB1 3894/4885ADRB3 3963/4885 |
| US-20220242815-A1 | COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | PHOSPHO1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GRIN2C | ADRB2 86/4885ADRB1 462/4885ADRB3 352/4885 |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADRB2 4151/4885ADRB1 3894/4885ADRB3 3963/4885 |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADRB2 4151/4885ADRB1 3894/4885ADRB3 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.